Skip to main navigation Skip to search Skip to main content

Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry

  • Abi Selvarajah
  • , Annerieke H. Tavenier
  • , Wilbert L. Bor
  • , Vital Houben
  • , Saman Rasoul
  • , Eliza Kaplan
  • , Koen Teeuwen
  • , Sjoerd H. Hofma
  • , Erik Lipsic
  • , Giovanni Amoroso
  • , Maarten A.H. van Leeuwen
  • , Jur M. ten Berg
  • , Arnoud W.J. van ‘t Hof
  • , Renicus S. Hermanides*
  • *Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Article number1–3
JournalEuropean heart journal open
Volume1
Issue number3
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • Cangrelor
  • P2Y12 inhibitors
  • Percutaneous coronary intervention
  • Platelet inhibition

Cite this